Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
Yonghui Sun(Tsinghua University), Yu Rao(Soochow University), Yuqin Song(Peking University), Zimo Yang(University of Electronic Science and Technology of China), Ning Ding(Nanjing University of Chinese Medicine), Wanli Liu(Center for Life Sciences), Jun Zhu(Peking University)
Cited by 144
Related Papers
PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
|Cell Research|2018|280
Chemistries of bifunctional PROTAC degraders
|Chemical Society Reviews|2022|270